Cargando…
Biomarkers of Cutaneous Leishmaniasis
Cutaneous leishmaniasis (CL) is an immune-mediated skin pathology caused mainly by Leishmania (L.) major, Leishmania tropica, Leishmania braziliensis, L. mexicana, and L. amazonensis. The burden of CL in terms of morbidity and social stigmas are concentrated on certain developing countries in Asia,...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029629/ https://www.ncbi.nlm.nih.gov/pubmed/29998089 http://dx.doi.org/10.3389/fcimb.2018.00222 |
_version_ | 1783336999834353664 |
---|---|
author | Bahrami, Fariborz Harandi, Ali M. Rafati, Sima |
author_facet | Bahrami, Fariborz Harandi, Ali M. Rafati, Sima |
author_sort | Bahrami, Fariborz |
collection | PubMed |
description | Cutaneous leishmaniasis (CL) is an immune-mediated skin pathology caused mainly by Leishmania (L.) major, Leishmania tropica, Leishmania braziliensis, L. mexicana, and L. amazonensis. The burden of CL in terms of morbidity and social stigmas are concentrated on certain developing countries in Asia, Africa, and South America. People with asymptomatic CL represent a large proportion of the infected individuals in the endemic areas who exhibit no lesion and can control the infection by as yet not fully understood mechanisms. Currently, there is no approved prophylactic control measure for CL. Discovery of biomarkers of CL infection and immunity can inform the development of more precise diagnostics tools as well as curative or preventive strategies to control CL. Herein, we provide a brief overview of the state-of-the-art for the biomarkers of CL with a special emphasis on the asymptomatic CL biomarkers. Among the identified CL biomarkers so far, direct biomarkers which indicate the actual presence of the infection as well as indirect biomarkers which reflect the host's reaction to the infection, such as alterations in delayed type hypersensitivity, T-cell subpopulations and cytokines, adenosine deaminase, and antibodies against the sand fly saliva proteins are discussed in detail. The future avenues such as the use of systems analysis to identify and characterize novel CL biomarkers are also discussed. |
format | Online Article Text |
id | pubmed-6029629 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-60296292018-07-11 Biomarkers of Cutaneous Leishmaniasis Bahrami, Fariborz Harandi, Ali M. Rafati, Sima Front Cell Infect Microbiol Cellular and Infection Microbiology Cutaneous leishmaniasis (CL) is an immune-mediated skin pathology caused mainly by Leishmania (L.) major, Leishmania tropica, Leishmania braziliensis, L. mexicana, and L. amazonensis. The burden of CL in terms of morbidity and social stigmas are concentrated on certain developing countries in Asia, Africa, and South America. People with asymptomatic CL represent a large proportion of the infected individuals in the endemic areas who exhibit no lesion and can control the infection by as yet not fully understood mechanisms. Currently, there is no approved prophylactic control measure for CL. Discovery of biomarkers of CL infection and immunity can inform the development of more precise diagnostics tools as well as curative or preventive strategies to control CL. Herein, we provide a brief overview of the state-of-the-art for the biomarkers of CL with a special emphasis on the asymptomatic CL biomarkers. Among the identified CL biomarkers so far, direct biomarkers which indicate the actual presence of the infection as well as indirect biomarkers which reflect the host's reaction to the infection, such as alterations in delayed type hypersensitivity, T-cell subpopulations and cytokines, adenosine deaminase, and antibodies against the sand fly saliva proteins are discussed in detail. The future avenues such as the use of systems analysis to identify and characterize novel CL biomarkers are also discussed. Frontiers Media S.A. 2018-06-26 /pmc/articles/PMC6029629/ /pubmed/29998089 http://dx.doi.org/10.3389/fcimb.2018.00222 Text en Copyright © 2018 Bahrami, Harandi and Rafati. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Bahrami, Fariborz Harandi, Ali M. Rafati, Sima Biomarkers of Cutaneous Leishmaniasis |
title | Biomarkers of Cutaneous Leishmaniasis |
title_full | Biomarkers of Cutaneous Leishmaniasis |
title_fullStr | Biomarkers of Cutaneous Leishmaniasis |
title_full_unstemmed | Biomarkers of Cutaneous Leishmaniasis |
title_short | Biomarkers of Cutaneous Leishmaniasis |
title_sort | biomarkers of cutaneous leishmaniasis |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029629/ https://www.ncbi.nlm.nih.gov/pubmed/29998089 http://dx.doi.org/10.3389/fcimb.2018.00222 |
work_keys_str_mv | AT bahramifariborz biomarkersofcutaneousleishmaniasis AT harandialim biomarkersofcutaneousleishmaniasis AT rafatisima biomarkersofcutaneousleishmaniasis |